UK Website

ONTOZRY® can reduce seizure
frequency in adults with
uncontrolled focal onset seizures1,2

ONTOZRY® is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled, despite treatment with at least 2 anti-epileptic medicinal products.1

ONTOZRY® reduces seizure frequency by at least 50% in over half of patients – and can lead to seizure freedom in some patients2

ONTOZRY® explained: a dual
mechanism of action

Prescribing and
titrating ONTOZRY®

ONTOZRY®
tolerability data

HIGHLIGHTS FROM the ONTOZRY® Live Forum

Read about and listen to conversations from the Ontozry® Live Forum which was co-chaired by globally respected epilepsy specialists Prof Ley Sander, Dr Rhys Thomas and Phil Tittensor

Reference:

1. ONTOZRY® Summary of product characteristics. 2. Krauss GL, et al. Lancet Neurol. 2020;19(1):38-48.

P-UK-CE-2100008 | December 2021

Feedback